We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ABNX market cap is 39.47M. The company's latest EPS is EUR -0.1084 and P/E is -11.25.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 0 | 0 | 678k | 5.28M | 4.74M |
| Operating Income | -2.53M | -2.97M | -5.95M | -3.99M | -3.41M |
| Net Income | 1.85M | -1.89M | -5.82M | -4.21M | -3.52M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 10.25M | 10.29M | 21.83M | 15.82M | 14.83M |
| Total Liabilities | 3.58M | 3.66M | 11.16M | 8.65M | 6.91M |
| Total Equity | 6.67M | 6.63M | 10.68M | 7.17M | 7.92M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -3.95M | -599k | -6.69M | -3.36M | -3.7M |
| Investing | N/A | -125k | 1.34M | -175k | -130k |
| Financing | 824k | 1.55M | 3.97M | -194k | 3.89M |
| Market Cap | 39.47M |
| Price to Earnings Ratio | -11.25 |
| Price to Sales Ratio | 8.36 |
| Price to Cash Ratio | 9.65 |
| Price to Book Ratio | 5 |
| Dividend Yield | - |
| Shares Outstanding | 32.46M |
| Average Volume (1 week) | 33.2k |
| Average Volume (1 Month) | 39.69k |
| 52 Week Change | -4.70% |
| 52 Week High | 1.50 |
| 52 Week Low | 0.91 |
| Spread (Intraday) | 0.03 (2.25%) |
| Company Name | Abionyx Pharma |
| Address |
33-43 avenue georges pompidou, batiment d balma, haute-garonne 31130 |
| Website | https://www.abionyx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
